Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396496 · ClinicalTrials.gov registry record · Phase 2
Treatment of POEMS Syndrome With Daratumumab
A Phase 2 study of POEMS Syndrome, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04396496 is a Phase 2 study of POEMS Syndrome that has completed, run by University of Arkansas. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04396496, a Phase 2 study of POEMS Syndrome, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy, Organomegaly, Endocrinopathy, m Protein Component, Skin Changes (POEMS) syndrome. This trial will enroll ten subjects, who will complete 12 four-week cycles of DARA, in combination with the immunomodulatory drug (IMiD) lenalidomide. Objectives of this study include improvement in neuropathy and performance status, as well as improvement in laboratory values and survival.
Conditions Studied
Interventions
- DRUG Daratumumab Injection
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2023-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04396496
The ClinicalTrials.gov registry entry for NCT04396496 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with POEMS Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab Injection is the first listed.
NCT04396496 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT04396496 about?
NCT04396496 is a clinical study titled "Treatment of POEMS Syndrome With Daratumumab". This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy, Organomegaly, Endocrinopathy, m Protein Component, Skin Changes (POEMS) syndrome. This trial will enroll ten subj...
What is the current status of trial NCT04396496?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-09-22. Estimated completion is 2023-10-16.
What conditions does trial NCT04396496 study?
This clinical trial studies the following conditions: POEMS Syndrome.
What interventions are being tested in trial NCT04396496?
The interventions under investigation include: Daratumumab Injection (DRUG).
Who is sponsoring clinical trial NCT04396496?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04396496 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.